AstraZeneca
AZN
905 hedge funds and large institutions have $31.1B invested in AstraZeneca in 2021 Q3 according to their latest regulatory filings, with 196 funds opening new positions, 418 increasing their positions, 153 reducing their positions, and 50 closing their positions.
292% more first-time investments, than exits
New positions opened: 196 | Existing positions closed: 50
173% more repeat investments, than reductions
Existing positions increased: 418 | Existing positions reduced: 153
55% more funds holding in top 10
Funds holding in top 10: 11 → 17 (+6)
48% more call options, than puts
Call options by funds: $925M | Put options by funds: $625M
19% more capital invested
Capital invested by funds: $26B → $31.1B (+$5.05B)
18% more funds holding
Funds holding: 768 → 905 (+137)
0.15% more ownership
Funds ownership: 16.53% → 16.68% (+0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$836M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$544M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$453M |
| 4 |
Renaissance Technologies
New York
|
+$389M |
| 5 |
Legal & General Group
London,
United Kingdom
|
+$319M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$658M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$221M |
| 3 |
Goldman Sachs
New York
|
-$181M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$108M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$63.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SL
951
Savior LLC
Wellesley Hills,
Massachusetts
| – | -$2K | -15 | Closed |
|
|
FFG
952
Ford Financial Group
Fresno,
California
| – | -$1K | -10 | Closed |
|
953
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| – | +$116 | +1 | New |
|
|
SOW
954
State of Wyoming
Cheyenne,
Wyoming
| – | +$116 | +1 | New |
|
AZN Hedge Fund Activity: Q3 2021 in Review
905 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2021, worth a combined $31.1B — up 19% from $26B a quarter earlier.
Buyers outnumbered sellers: 196 funds opened new AZN positions and 50 closed out — a net gain of 146 holders — while 418 added to existing stakes and 153 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $836M. The largest seller was Citigroup, cutting an estimated $658M.
- 905 institutional investors held AstraZeneca (AZN) as of Q3 2021, up from 768 in Q2 2021.
- Funds reported $31.1B of AstraZeneca stock for Q3 2021, up 19% quarter-over-quarter.
- 196 funds opened new AstraZeneca positions in Q3 2021 and 50 closed out, a net change of +146 holders.
- The largest AstraZeneca buyer in Q3 2021 was T. Rowe Price Associates, an estimated $836M added.
- The largest AstraZeneca seller in Q3 2021 was Citigroup, an estimated $658M sold.
Based on aggregated 13F filings for Q3 2021.